Shanghai Heartcare IPO: Thoughts on First Day Trading
We expect Heartcare’s IPO to remain under pressure at its open due to uncertainty regarding the lawsuit with Medtronics despite being priced at a...
554 Views
Heartcare (心玮医疗) IPO Trading: Risk-Off for Institutional Investors
We analyze the new information for HeartCare IPO. We think the demand is not strong and debut performance will be under pressure given the overhang...
406 Views
Acotec Scientific IPO: Valuation Insights
Our base-case DCF valuation is HK$21.65 per share, which is a -6% downside to the mid-point of the IPO price range. Consequently, we think the...
482 Views
Shanghai Heartcare IPO: DCF Offers Decent Upside but Mind the Ongoing Lawsuit with Medtronic
Our DCF valuation offers a price per share of HK$182.78 which is 6.9% higher than the upper end of the company’s indicative IPO price range of...
514 Views
Shanghai HeartCare Medical IPO: Valuation Insights
Our base-case DCF valuation is HK$186.51 per share, which is a 13% upside to the mid-point of the IPO price range of HK$160.00-171.00 per share.
839 Views